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Summary
 
The receptor for granulocyte/macrophage colony-stimulating factor (GM-CSF) is composed
of two chains, 
 
a
 
 and 
 
b
 
c. Both chains belong to the superfamily of cytokine receptors charac-
terized by a common structural feature, i.e., the presence of at least two fibronectin-like folds
in the extracellular domain, which was first identified in the growth hormone receptor. The
GM-CSF receptor (GMR)-
 
a
 
 chain confers low affinity binding only (5–10 nM), whereas the
other chain, 
 
b
 
c, does not bind GM-CSF by itself but confers high affinity binding when asso-
ciated with GMR-
 
a
 
 (25–100 pM). The present study was designed to define the assembly of
the GMR complex at the molecular level through site-directed mutagenesis guided by homol-
ogy modeling with the growth hormone receptor complex. In our three-dimensional model,
R280 of GMR-
 
a
 
, located in the F
 
9
 
–G
 
9
 
 loop and close to the WSSWS motif, is in the vicinity
of the ligand Asp112, suggesting the possibility of electrostatic interaction between these two
residues. Through site directed mutagenesis, we provide several lines of evidence indicating the
importance of electrostatic interaction in ligand–receptor recognition. First, mutagenesis of
GMR-
 
a
 
R280 strikingly ablated ligand binding in the absence of 
 
b
 
 common (
 
b
 
c); ligand bind-
ing was restored in the presence of 
 
b
 
c with, nonetheless, a significant shift from high (26 pM)
toward low affinity (from 2 to 13 nM). The rank order of the dissociation constant for the dif-
ferent GMR-
 
a
 
R280 mutations where Lys 
 
. 
 
Gln 
 
. 
 
Met 
 
. 
 
Asp, suggesting the importance of
the charge at this position. Second, a mutant GM-CSF with charge reversal mutation at posi-
tion Asp112 exhibited a 1,000-fold decrease in affinity in receptor binding, whereas charge ab-
lation or conservative mutations were the least affected (10–20-fold). Third, removal of the
charge at position R280 of GMR-
 
a
 
 introduced a 10-fold decrease in the association rate con-
stant and only a 2-fold change in the dissociation rate constant, suggesting that R280 is impli-
cated in ligand recognition, possibly through interaction with Asp112 of GM-CSF. For all
R280 mutants, the half-efficient concentrations of GM-CSF required for membrane (receptor
binding) to nuclear events (c-fos promoter activation) and cell proliferation (thymidine incor-
poration) were in the same range, indicating that the threshold for biologic activity is governed
mainly by the affinity of ligand–receptor interaction. Furthermore, mutation of other residues
in the immediate vicinity of R280 was less drastic. Sequence alignment and modeling of inter-
leukin (IL)-3R and IL-5R identified an arginine residue at the tip of a 
 
b
 
 turn in a highly diver-
gent context at the F
 
9
 
–G
 
9
 
 loop, close to a conserved structural element, the WSXWS motif,
suggesting the possibility of a ligand association mechanism similar to the one described herein
for GMR.
 
C. Cadieux and D. Rajotte contributed equally to this work.
  
1940
 
Granulocyte/Macrophage Colony-stimulating Factor Receptor Assembly
 
H
 
uman GM-CSF is a cytokine that promotes the pro-
liferation, survival, and functional activation of cells
in the granulocytic and monocytic lineage (1–4). Gene
cloning indicates that the receptor for GM-CSF is com-
posed of two chains, 
 
a
 
 (5) and 
 
b
 
 (6). The human GM-CSF
receptor (GMR)-
 
a
 
 subunit is 378 amino acid (aa)
 
1
 
 in length
(5), most of which constitutes the extracellular domain.
GMR-
 
a
 
 confers low affinity binding and has been shown
to be species specific for its ligand (5, 7), whereas 
 
b
 
, which
is required for signal transduction, comprises 881 aa with a
432 aa cytoplasmic tail (6). Both 
 
a
 
 and 
 
b
 
 cytoplasmic do-
mains lack intrinsic enzymatic activities. Interestingly, the
 
b
 
 chain, referred to as 
 
b
 
 common or 
 
b
 
c, is shared with the
receptors for IL-3 and -5, two cytokines that exhibit signif-
icant overlap in biological activity with GM-CSF (for re-
view see reference 8). Our previous data suggest that the
transition from low affinity to high affinity binding results
from the association of 
 
b
 
c to the GM-CSF–GMR-
 
a
 
 com-
plex, resulting in a more stable ternary complex (9). Data
from many groups also suggest that only the high-affinity
receptor mediates the biologic response of the cells to GM-
CSF (3, 5, 7). Expression of the two chains of the GM-
CSF receptor in NIH 3T3 cells results in GM-CSF–induced
signal transduction (10), morphological transformation (11,
12), and cell proliferation (13).
Both chains of the GM-CSF receptor are members of the
superfamily of cytokine receptors, characterized by con-
served structural features in the extracellular domain, i.e.,
four conserved cysteine residues, and a typical WSXWS mo-
tif in the juxtamembrane region. According to the model
predicted by Bazan (14), cytokine receptors are made up of
two domains, each containing seven antiparallel 
 
b
 
 strands sim-
ilar to the fibronectin fold. These strands are coded A–G for
the NH
 
2
 
-terminal domain and A
 
9
 
–G
 
9
 
 for the COOH-termi-
nal domain. Together, these two domains form a common
cytokine receptor motif (CRM). This predicted structure
was confirmed through crystallization of the growth hor-
mone (GH)–GHR complex (15) and of the tenth type III
segment of human fibronectin (16). The tenth segment of fi-
bronectin has, in fact, been shown to bind integrin through
the RGD site located at the F–G loop. Furthermore, scan-
ning mutagenesis of IL-6R-
 
a
 
 also identified several resi-
dues in the same region, E278/F279, and surrounding resi-
dues (A275, G282/E283) as essential for IL-6 binding (17).
These data indicate a clustering of residues that are impor-
tant in ligand–receptor recognition at the F
 
9
 
–G
 
9
 
 loop of
the CRM.
GMR-
 
a
 
 plays a critical role in receptor complex forma-
tion because it confers the specificity of association with the
ligand and it is involved in signal transduction as shown by
our team (12) and others (18). Therefore the aim of this
work was to identify the molecular determinants of the
complex formation on GMR-
 
a
 
, through site directed mu-
tagenesis guided by homology modeling based on the GH–
GHR complex. Functionally important residues have to be
in the vicinity of residues on the ligand that are crucial for
receptor binding and to be located in a divergent context
compared to IL-3R-
 
a
 
 and -5R-
 
a
 
. We have thus identified
the critical role of R280 located at the F
 
9
 
–G
 
9
 
 loop of
GMR-
 
a
 
 in ligand binding.
 
Materials and Methods
 
Homology Modeling of the GM-CSF Hormone Receptor Com-
plex.
 
All calculations were performed using the software pack-
age SYBYL (Tripos Assoc., St. Louis, MO) on a SiliconGraphics
Indigo
 
2
 
-Extreme workstation. The Kollman united atom force
field was used for energy calculations, and a dielectric constant of
10 was used to approximate a protein receptor environment. The
x-ray crystal structure of human growth hormone (hGH) bound
to its receptor (15) was obtained from the Brookhaven protein
database. Before manipulations, the entire complex was subjected
to 1,000 steps of conjugate gradient minimization. GMR-
 
a
 
 has one
CRM as GHR, whereas 
 
b
 
c has a duplicated extracellular domain
with two such CRM. Using the sequence alignment of Goodall
et al. (19) the extracellular domain of molecule 1 (GHRI) and
GHRII chains of the GH–GHR
 
2
 
 complex were transformed one
amino acid at a time into the GM-CSF receptor 
 
a
 
 chain and the
membrane proximal CRM motif of 
 
b
 
c, respectively. The back-
bone dihedryl angles were held fixed to preserve the receptor’s
secondary structure, whereas the amino acid side chains were po-
sitioned using the scan subroutine in SYBYL. This routine rotates
each side chain dihedryl angle until a sterically acceptable confor-
mation was obtained. The x-ray crystal structure of GM-CSF has
been reported (20). The hGH ligand was excised from the hor-
mone receptor complex and the GM-CSF ligand was positioned
into the receptor visually in approximately the same orientation
and position as was hGH. When the new ligand–receptor com-
plex displayed reasonable steric complementarity, the entire com-
plex was minimized as above, allowing all atoms to relax. A mo-
lecular dynamics simulation of 20 ps was performed to determine
the stability of the GM-CSF receptor complex, and it was deter-
mined that the complex retained its secondary structure. Point
mutations of the new GM-CSF receptor and hormone were per-
formed using the same methodology, and the stability of each
new complex was determined using energy calculations as well as
short (5–10 ps) molecular dynamics simulations.
The same approach was used to construct the model of IL-3, -5,
and Epo hormone receptor complex. Since the crystal structures
of IL-3 and Epo are not available, we used the GM-CSF and GH
coordinates as templates for the hormone in the IL-3 and Epo re-
ceptor complex models, respectively, for the following reasons.
On one hand, structure prediction for IL-3 (21) and nuclear mag-
netic resonance data of a human IL-3 variant (22) show that the
IL-3 structure is folded into the same up-up-down-down ar-
rangement of the four helices bundle observed for the GM-CSF
structure. On the other hand, the 
 
a
 
 helices of erythropoietin are
longer and Epo is classified as a long chain helical-bundle subclass,
to which belongs growth hormone (23).
 
Site-directed Mutagenesis of Human GM-CSF and of GMR-
 
a
 
.
 
The human GM-CSF cDNA was mutated at the indicated posi-
tions (Table 1), expressed in 
 
Escherichia coli
 
 and purified as de-
scribed (24). The GMR-
 
a
 
 cDNA was cloned in the expression
vector pME18S (10). The cDNA for 
 
b
 
c (KH97) was cloned in
 
1
 
Abbreviations used in this paper:
 
 
 
b
 
c, 
 
b
 
 common; aa, amino acid; CHO,
Chinese hamster ovary; CRM, cytokine receptor motif; GH, growth
hormone; GMR, GM-CSF receptor; hGH, human growth hormone;
NIH, National Institutes of Health. 
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the same vector, but without the neomycin selectable gene. Both
were provided by Dr. Toshio Kitamura (DNAX, Palo Alto, CA).
GMR-
 
a
 
 cDNA bearing point mutations at position R280 were
generated by PCR site-directed mutagenesis. The forward oligos
used to generate the various point mutations were tcagagctgca-
gacgtcgaaatctt (GMR-
 
a
 
R280E), tcagagctgcagacgtcaagatctt (GMR-
 
a
 
R280K), tcagagctgcagacgtcatgatctt (GMR-
 
a
 
R280M), and tca-
gagctgcagacgtccagatctt (GMR-
 
a
 
R280Q). In all reactions, the
reverse oligo used was gctttatttgtgaaatttgtgatg. The pME18 vector
containing the full GMR-
 
a
 
 cDNA was used as a template for
PCR reactions and the annealing temperature was 58
 
8
 
C. Purified
PCR fragments of mutated GMR-
 
a
 
 were digested by PstI and
inserted into the same site of the complete GMR-
 
a
 
 cDNA
cloned into the pGEM7 vector (Promega Corp., Madison, WI).
Excised EcoRI fragments of pGEM7 vector containing a mutant
version of GMR-
 
a
 
 were inserted into the same site of the
pME18S expression vector containing the full GMR-
 
a
 
 cDNA.
Resulting clones were sequenced to confirm presence of the
point mutation and that no other mutations were present in the
PCR amplified region.
Double mutations at two positions, Asp278Val279 (D278V279)
and Ile281Leu282 (I281L282), as well as single mutations of Asp278
(D278) were generated through a similar approach with the
following primers aagatcagagctgcagccgcccgcatct (GMR-
 
a
 
D278-
AV279A),  tgaagatcagagctgcacagcagcgcatct (GMR-
 
a
 
D278QV27-
9Q), tgaagatcagagctgcagccgtccgcatct (GMR-
 
a
 
D278A), tgaagatca-
gagctgcaaacgtccgcatct (GMR-
 
a
 
D278N), atcagagctgcagacgtccgc-
gccgccaattgg (GMR-
 
a
 
I281AL282A), and atcagagctgcagacgtccgc-
cagcagaattgg (GMR-
 
a
 
I281QL282Q).
 
Transient Expression of GMR-
 
a
 
 and 
 
b
 
c at the surface of NIH
3T3. The GMR-a and bc cDNA were co-transfected by the
calcium phosphate method (12, 13) in exponentially growing
NIH 3T3 cells at a 1:1 ratio. In brief, 1 d before transfection,
200,000 cells were seeded in 60-mm tissue culture dishes. On the
day of transfection, 400 ml of DNA-Ca3(PO4)2 precipitate con-
taining 12 mg of DNA was added to the culture and incubated for
16 h. Cells were then washed with PBS and split into replicate
24-well plates at a concentration of 75,000 cells/well. Each day
after plating, the cells were used for either binding, cross-linking,
or proliferation assays. Kinetics studies indicate the GM-CSF
binding and GM-CSF–dependent cell proliferation was optimal
on day 2 after transfection (data not shown). This time point was
selected for all subsequent experiments.
Chinese hamster ovary (CHO) cell lines stably expressing the
low affinity GMR-a were isolated as described previously (24).
Iodinated GM-CSF Binding Assays. Purified recombinant GM-
CSF was iodinated with the Bolton–Hunter reagent (DuPont–
New England Nuclear, Wilmington, DE). The specific activity of
the radioligand was determined by radioimmunoassay (7) and
confirmed independently by ELISA (25). NIH 3T3 cells were
co-transfected with wild-type or mutant GMR-a and bc chain
by the Ca-PO4 method as described. After an overnight incuba-
tion, transfected cells were seeded to half confluency in 24-well
culture dishes. 2 d after transfection, ligand-binding assay was
performed at 48C for 3 h in IMDM (without bicarbonate) sup-
plemented with 1% BSA. Nonspecific binding was determined in
the presence of 100-fold excess unlabeled GM-CSF. After bind-
ing, cells were washed twice with ice-cold PBS and collected by
the addition of 200 ml of trypsin. Concentrations of radioligands
used for all saturation curves were in the range of 20 pM–20 nM
as indicated. Complete competition curves were performed with
500 pM of wild-type radioligand and varying concentrations of
wild-type or mutant GM-CSF that were in the range of 0–40 nM.
Binding constants were estimated through computer modeling with
the program ALLFIT, based on a nonlinear curve fitting routine
as described previously (7, 9, 26).
Kinetics of GM-CSF Binding. The association rate constants (Kon)
were estimated by analysis of the kinetics of association at three
different concentrations of radioligand for a time range of 5–120
min using the following equations. First, the kinetics of associa-
tion for increasing concentrations of radioligand were subjected
to linear transformation using the equation ln (Be/[Be 2 Bt]) 5
Kob 3 t, where Be is the observed binding at equilibrium and Bt
the binding observed at a given time t. Linear regression of the
slopes of these lines (Kob) as a function of ligand concentrations
provided an estimate of the association rate constant Kon. For dis-
sociation experiments, 125I–GM-CSF binding was performed at
equilibrium at a concentration of 2 nM of radioligand. Cells were
then incubated with a 100-fold excess of cold GM-CSF in
IMDM 1% BSA for time periods ranging from 5 to 110 min. Su-
pernatants were removed before counting of bound GM-CSF.
The dissociation rate constant (Koff) was estimated using the fol-
lowing equation: ln (Bt/Bo) 5 2Koff 3 t where Bo is the specific
binding at equilibrium before dissociation, and Bt is the specific
binding remaining after a period of t minutes.
Immunodetection of GMR-a, Cell Proliferation, and c-fos Promoter
Assay. Surface expression of wild-type and mutant GMR-a
were quantitated by whole cell immunoperoxidase assay using the
monoclonal mouse anti–human GMR-a (Upstate Biotechnology
Inc., Lake Placid, NY) as described previously (12). Cell prolifer-
ation was assessed by tritiated thymidine (DuPont–New England
Nuclear) incorporation at a final concentration of 3 mCi/ml in
serum-free medium (13) 48 h after transfection. The wild-type
c-fos promoter luciferase reporter construct (3 mg) (17) was co-
transfected with the various GMR-a (3 mg) and wild-type bc (3
Table 1. Binding of Mutant GM-CSF to Wild-type GMR-a
GM-CSF position Mutation Kd
nM
Wild type – 1.7
E 108 A 3.8
Q 8.1
K 3.0
N 109 D 2.8
A 15.0
K 7.9
K 111 A 1.4
Q 2.7
E 2.1
D 112 N 19
A3 1
R 335
K 1,400
CHO cells expressing the GMR-a chain were generated as described
in Materials and Methods. Mutations in GM-CSF were introduced at
the indicated position by site directed mutagenesis and expressed in E.
coli. Kds of the various purified GM-CSF mutants were determined by
competition analysis on GMR-a–transfected CHO cells.1942 Granulocyte/Macrophage Colony-stimulating Factor Receptor Assembly
mg) in NIH 3T3 by the calcium-phosphate method. Transiently
transfected cells were then incubated for 24 h in serum-free medium
in the presence or absence of GM-CSF, lysed, and luciferase activity
was determined in nuclear extract as described (13) after adjustment
for growth hormone activity driven by the Rous sarcoma virus
LTR (2 mg), which was co-transfected as an internal control.
Results
Modeling GM–GMR Interaction Based on the Crystal Struc-
ture of the GH–GHR Complex. The initial event in GH
binding to its receptor is the association of site 1 on GH
with GHRI to form a 1:1 complex (binding affinity, disso-
ciation constant [Kd] 5 0.3 nM), followed by the associa-
tion of site 2 with GHR molecule 2 (GHRII) to form a
ternary complex GH–GHR2 (27, 28). The first binding
step involving GHRI results in the burial of a 1,230-Å sur-
face, whereas only 900 Å is buried on binding of GHRII,
consistent with a higher affinity of interaction of GHRI
with site 1. The modeling for GMR-a is therefore based
on GHRI interaction with site 1 and for bc on GHRII in-
teraction with site 2. Our model identifies a contact surface
between bc and the ligand that includes H367 on bc (29,
30) and residue E21 (31) on the ligand as previously docu-
mented (Fig. 1). Finally, domains of the ligand that appear
to be involved in intermolecular contacts correspond to
those identified previously through the use of human
mouse chimeras (32), and of truncated GM-CSF (33) i.e.,
helix A, the AB loop, and helix D.
Importance of the Negative Charge at Position 112 of GM-
CSF Defined by Site-directed Mutagenesis.  Modeling iden-
tified several hydrophilic and charged surface residues of
helix D of GM-CSF as potential contact points with
GMR-a: E108, N109, K111, and D112. Sequence analysis
indicates that these are aligned with residues that are shown
to be at the interface of growth hormone with GHRI (28).
Mutations at two of these residues on GM-CSF, E108 and
D112, were previously shown to decrease ligand–receptor
binding (24). We therefore generated further mutations at
all four positions identified by modeling. Quantitative anal-
ysis of GM-CSF binding to CHO cells stably expressing
GMR-a alone was determined through complete compe-
tition curves for each mutant using wild-type radioligand as
a marker (Table 1). Our data indicate that charge removal
(Lys®Ala; Lys®Gln) or charge reversal (Lys®Glu) at resi-
due K111 did not significantly affect GM–GMR-a recog-
nition. Similarly, mutations at positions E108 and N109 re-
sulted only in a 2–9-fold shift in affinity as compared to
wild-type ligand. Finally, the most drastic effect was seen
with the D112 mutants; there was a 12–800-fold shift in
Kd depending on the mutation, and the rank order was
D112N , D112A , D112K. Thus, the least affected was
the Asp to Asn mutation, which represents a shift in iso-
electric point from 3 to 5.4. In addition, the Kd of Asp to
Ala substitution was only slightly higher than that of the
Asn mutant. In contrast, it is revealing that the charge re-
versal mutants (Asp®Lys and Asp®Arg) resulted in a dras-
tic shift in Kd to the right. This rank order indicates that
Figure 1. Homology model-
ing of the GM-CSF receptor
complex with its ligand on the
basis the crystal structure of the
growth hormone complex. The
extracellular domains of GMR-a
(left) and membrane proximal
CRM of bc (right) are shown
complexed with GM-CSF, each
receptor chain being organized
in two fibronectin-like domains
with seven b strands. This repre-
sentation of the GM–GMR
complex is based on the structure
of the GH–GHR2 complex and
was generated as described in the
Materials and Methods. a helices
are shown in blue and b strands
in red. Two basic surface resi-
dues (white) that are potentially
involved in electrostatic interac-
tion with surface residues (ma-
genta) on the ligand are high-
lighted. The location of the
conserved WSXWS motif is
shown in green. R275 located
on the F9 strand, potentially in-
volved in p-cation interaction
with the two Trp residues of the
WSSWS box (similarly observed
in the crystal structure of EpoR
complexed with a peptide
ligand, 40), is shown in blue.1943 Rajotte et al.
the interaction between D112 and the receptor is mainly
electrostatic.
Proximity of R280 of GMR-a and D112 of the Ligand.
Because of the importance of the charge at position 112 of
the ligand, the residues surrounding D112 were further
evaluated in the ligand–receptor binding pocket of the
three-dimensional GM–GMR model shown in Fig. 1. The
acidic residue D112 is oriented towards GMR-a and is po-
sitioned at a distance of 3–4.7 Å from the basic residue
R280. The estimated distance remains within the possibil-
ity of intermolecular interaction at this position. For exam-
ple, E21 on GM-CSF is located within 4.19 Å of H367 on
bc. We therefore proceeded to site-directed mutagenesis of
R280 of GMR-a.
Loss of GM-CSF Binding to the GMR-aR280 Mutants.
Several mutations were introduced at this position on the basis
of charge conservation (R280K), charge removal (R280Q),
and hydrophilic to hydrophobic conversion (K280M) or
charge reversal (R280E). NIH 3T3 cells were transiently
transfected with these various GMR-a mutants alone and
submitted to GM-CSF binding assays. All of the mutants
showed a complete loss of specific binding compared to the
wild-type GMR-a chain at 2 nM of iodinated GM-CSF
(Fig. 2 A), a concentration shown to be in the range of the
Kd of the low affinity GM-CSF binding site. Even at high
concentrations of GM-CSF (i.e., 8–20 nM) we did not de-
tect any specific binding for three mutants tested, R280K,
R280M, and R280E (data not shown). All GMR-aR280
mutants were detected by the anti–GMR-a antibody in an
immunoperoxidase assay (Fig. 2 B). This indicates that the
mutations did not induce important structural changes or
modification of the expression level of GMR-a. Further-
more, mutation of another surface Arg into Gln, R258Q,
did not affect ligand binding in the absence (data not
shown) or in the presence of bc (see Table 3). These data
underscore the crucial role of R280 in GM-CSF binding
by GMR-a.
Physical Interaction of Mutated GMR-a with bc Restores
Ligand Binding with Intermediate to Low Affinity. GM-CSF
binding assays were performed with mutated GMR-a and
bc. Surprisingly, specific binding was detected in all cases,
but was drastically reduced as compared to the wild-type
receptor (Fig. 3 and Table 2). Cotransfection of wild-type
GMR-a and bc results in both high and low affinity GM-
CSF binding (6). In contrast, all GMR-a R280 mutants
exhibit a single GM-CSF binding site of intermediate to low
affinity with Kds in the following order: R280K , R280Q
, R280M  , R280E. The extensive loss of binding of
GMR-a R280E in presence of bc indicates a charge effect
at this position. As bc alone does not bind the ligand (data not
shown), one can conclude that a mutated GMR-a can asso-
ciate with wild-type bc to form a lower affinity complex.
Association between GMR-a and bc may create addi-
tional contact points between GMR-a and the ligand itself,
in addition to R280. To address this question, we cotrans-
fected the mutant aR280M with either wild-type bc or
bH367A that can no longer form a high affinity GM-CSF
complex. In contrast to wild-type bc, cells expressing
aR280M and bH367A were unable to bind GM-CSF
(Fig. 3). Hence, preassociation with bc is unlikely to create
additional contact points between GMR-a and the ligand
apart from those that are affected by the mutations.
Comparative Kinetics of Binding of R280M Mutant and
Wild-type GMR-a. Previous observations (5, 34) suggest
that the difference in Kd between low (GMR-a alone) and
high (GMR-a–bc) affinity GM-CSF binding sites is mainly
due to differences in the dissociation rate constants, whereas
the association rate constants are in the same range. We
therefore compared the binding kinetics of mutant GMR-
aR280M with that of wild-type GMR-a. The association
rate constant (on rate) was 10-fold lower for the mutant re-
ceptor, as compared to the wild-type receptor (Fig. 4 and
Table 3). In contrast, there was only a twofold difference in
the dissociation rate constants (off rate). These results sug-
gest that the 20–30-fold decrease in binding affinity ob-
Figure 2. Binding of wild-type GM-CSF to mutant GMR-a. NIH
3T3 cells were transiently transfected with wild-type or mutant forms of
the GMR-a chain (R280K, R280Q, R280M, R280E) as described in
Materials and Methods. (A) Triplicate cultures of transfected or nontrans-
fected (N.T.) cells were incubated with 2 nM of 125I–GM-CSF. Nonspe-
cific binding was determined by incubation with 2 nM 125I–GM-CSF and
100-fold excess of nonradiolabeled ligand. The residual amount of
125I–GM-CSF binding (,50 cpm) was reproducibly observed in non-
transfected NIH 3T3 cells due to incomplete competition of nonspecific
binding. (B) Triplicate cultures of transfected or nontransfected (N.T.)
cells were tested for GMR-a surface expression using an immunoperoxi-
dase assay as described in Materials and Methods. There is a low level of
endogenous peroxidase activity (,0.04) in untransfected cells because the
surface expression of GMR-a was determined on intact cells.1944 Granulocyte/Macrophage Colony-stimulating Factor Receptor Assembly
served for the GMR-aR280M mutant compared to wild-
type GMR is mainly due to a decrease in the association rate
constant. In comparison, mutation of another Arg residue,
R258Q, did not significantly affect the kinetic constants
(Table 3). Thus, the charge at position R280 of GMR-a is
essential for ligand recognition and association, which is
different from the role assigned to bc, i.e., stabilization of
the complex through a decrease in the dissociation rate of
the ligand.
The contribution of other residues in the F9–G9 loop sur-
rounding R280 was next defined (Table 3). Neither Ile281
nor Leu282 were affected by alanine substitution, whereas
a change to a hydrophilic residue (Gln) slightly affected the
on rate. We also found that the negative charge at position
278 was almost as important as the positive charge at posi-
tion 280 since mutation from Asp to Asn, which removed
the charge, reduced the on rate by 10-fold. The immu-
noreactivity of D278 mutants with the monoclonal anti-
GMR-a was reproducibly two- to three-fold higher than
that of wild-type GMR-a suggesting that the consequence
of the mutation was not confined to the Asp residue, but
may also have affected a local structure. Indeed the immu-
noreactivity of all other mutations was unaffected, and fur-
thermore, their surface expression was not affected in bind-
ing assays (as assessed by the maximum binding capacity, data
not shown). Thus charge removal at position 278 may result
in a better unfolding of the epitope recognized by anti–
GMR-a. The three-dimensional model indicates that Asp278
is oriented towards Lys191 located in the linker region be-
tween the two fibronectin folds of GMR-a, suggesting a
role in stabilization of GMR-a structure through electro-
static interaction.
Correlation Between Ligand Binding and the Biologically Ac-
tive Threshold for the Mutant GMR-aR280–bc Complex.
A proliferation assay was performed on transiently trans-
fected NIH 3T3 cells incubated for 40 h in serum-free me-
dium in the absence or in the presence of GM-CSF. In
cells expressing the wild-type receptor, GM-CSF induces a
dose-dependent increase in thymidine uptake with a pla-
teau stimulation at 1 nM (Fig. 5). When the wild-type
GMR-a chain was substituted by R280K, R280M, or
R280Q mutants, higher concentrations of GM-CSF were
needed to obtain a response, but a maximal induction of
2.5-fold could still be observed. For the R280E mutant, only
a weak proliferative response could be detected at 10 nM
of GM-CSF. The half-efficient concentrations for stimula-
tion of cell proliferation were in the same range as the Kd
of the receptor complex (Table 2). Similarly, stimulation of
c-fos promoter activity by GM-CSF followed the shift in
Kd as above (Fig. 5). The mutated receptor is, therefore,
Figure 3. Binding of wild-type GM-CSF to mutant GMR-a co-trans-
fected with wild-type or mutant bc. NIH 3T3 cells were transiently co-
transfected with either wild-type or mutant GMR-aR280M and wild-
type bc or bcH367A. 125I–GM-CSF saturation assays were performed as
described in Materials and Methods and Table 2. Data are typical of at
least two independent experiments. The curves passing through the data
were calculated with the program ALLFIT (9, 26). For wild-type a and
bc, data were better described by a two-binding site model (high and low
affinity), whereas the data observed with aR280M mutant and wild-type
bc were better described by a one binding site model (low affinity only).
There was no binding when aR280M were coexpressed with bH367A.
Kd values obtained for all GMR-a mutants are shown in Table 2.
Table 2. Binding of Wild-type GM-CSF by Mutated GMR-a
in Association with bc
a 1 wt b Kd EC50
nM nM
wt 0.03 0.08
R280K 0.9 1.8
R280Q 1.7 3.0
R280M 2.8 2.5
R280E 13 15.1
NIH 3T3 cells were transiently transfected with the indicated GMR-a
mutants and wild-type (wt) bc. Dissociation constants determined by
saturation analysis and competition analysis with 125I–GM-CSF were
similar. Data shown were determined by saturation analysis, using radio-
ligand concentrations that were in the range of 5 pM–30 nM. Nonspe-
cific binding was determined through the addition of a 200-fold excess
of cold GM-CSF. With wild-type GMR-a and bc, the data were bet-
ter described by a two-site model, a high-affinity binding site as shown
in the first row, and a low-affinity binding site of 2–20 nM, which were
also the values observed with GMR-a alone. In contrast, in the pres-
ence of mutant GMR-a and wild-type bc, the data were better de-
scribed by a one binding site equation. Half-efficient concentration
(EC50) for GM-CSF were estimated by analysis of the proliferation
curves shown in Fig. 5 with the program ALLFIT.1945 Rajotte et al.
still competent for initiating a biological response at con-
centrations of GM-CSF that are in the range of the Kd as
shown previously (3, 7). These data underscore the impor-
tance of GMR-a and of appropriate receptor assembly in
signaling. Furthermore, the threshold for biologic activity is
most likely governed by the affinity of ligand–receptor in-
teraction.
Discussion
In the present study, we provide evidence for an essential
contribution of R280 in establishing a salt bridge with
GM-CSF when binding was performed in the absence of
bc. Similarly, Asp112 on the ligand appears to play a crucial
role in receptor binding. The proximity of R280 on
GMR-a with Asp112 on the ligand strongly supports the
possibility of electrostatic interaction between these two
residues. In the presence of wild-type bc, our data indicate
that R280 contributes to high affinity GM-CSF binding
since mutations at this position result in a significant shift
towards low affinity binding. Together, our observations
indicate the crucial role of a single charged residue at the
F9–G9 loop of GMR-a in GM-CSF binding R280 that in-
teracts with an acidic residue on the ligand, most likely
Asp112.
Importance of the Charge at Positions R280 of GMR-a and
Asp112 of GM-CSF. Mutagenesis of a single residue can
potentially introduce structural perturbations that alter pro-
tein–protein interaction at positions not directly involved
in establishing contact points. In the case of GMR-a, given
the large size of Arg and its location at the tip of the loop,
we chose to substitute Arg with residues of larger chain size
than Ala, which is a common choice for substitution, for the
purpose of steric complementarity. In addition, all mutant
proteins reacted equally with a neutralizing monoclonal an-
tibody directed against wild-type GMR-a. This suggests that
mutations at position R280 of GMR-a are likely localized
to this residue without affecting the overall structure of the
protein.
The importance of the charge at positions R280 of
GMR-a and Asp112 of the ligand was inferred from the
rank order of a series of mutations that introduce a reduc-
tion in charge, a change in hydrophilic to hydrophobic res-
idue, or simply charge reversal. Among GMR-a mutants
evaluated in the context of wild-type bc, R280M and
R280Q behaved similarly because of a decrease in charge at
this position, whereas the conservative mutation R280K
was the least affected, and the charge reversal R280E was
drastically shifted in affinity. Similarly, mutations at Asp112
of GM-CSF displayed the expected rank order with the
charge reversal being the most drastically affected, whereas
homologous mutations at positions not crucial for receptor
binding, i.e., N109 or K111, were almost silent. Nonethe-
less, we were not able to observe a complementation be-
tween GM-CSF–D112K and GMR-a–R280E mutants,
possibly because mutations on the ligand were more exac-
erbated in phenotype due to their locating on the surface of
a structural element, i.e., an a helix. Together, our obser-
vations suggest a crucial role for the charge at these posi-
tions, not only for appropriate electrostatic interaction, but
also for the local context of the ligand-binding pocket.
R280 of GMR-a Contributes to Ligand Recognition by a
Factor of 10. The importance of electrostatic interactions
in hormone–receptor recognition was previously identified
for hGH. Indeed, mutations at Arg residues present on hGH
were shown to affect association by a factor of 20, although
each Arg individually may not have contributed by more
than a factor of 2–3 to the on rate (35). In contrast, we
identify here a single Arg at position 280 on GMR-a that
contributes to the on rate by a factor of 10, and to the off
rate by only a factor of 2, indicating its crucial role in ligand
recognition. Interestingly, the nature of ligand binding for
the GMR-aR280M–wild-type bc complex is intrinsically
different from that established for wild-type GMR-a alone,
despite the fact that the Kds for both receptors were in the
same nM range. The low affinity of GMR-a binding to
the ligand in the absence of bc may be attributed mainly to
a major difference in the off rate when compared to that of
the GMR-a–bc complex (5, 8, and our unpublished re-
sults), whereas the on rates were not significantly different,
Figure 4. Comparison of the kinetics for binding of wild-type GM-
CSF to wild-type GMR-a or R280M mutant co-transfected with wild-
type bc. Linear transformation of the dissociation curves are shown in
upper panel and of the association curves in lower panel. The slopes of
theses lines provide an estimate of the dissociation rate constants (Koff) and
the association rate constants (Kon), respectively, shown in Table 3. B0,
GM-CSF–specific binding at time 0; Bt, GM-CSF specifically bound at
time t; Kob, the slope of ln (Beq/[Beq 2 Bt]) as a linear function of t; Beq,
GM-CSF–specific binding at equilibrium; WT, wild type.1946 Granulocyte/Macrophage Colony-stimulating Factor Receptor Assembly
suggesting that recruitment of bc into the complex results
in stabilization. In contrast, mutations at position R280 of
GMR-a resulted in a drastic decrease in the on rate when
wild-type bc was present, indicating its crucial role in the
association step. Our observations further underscore the
importance of kinetic studies for molecular recognition pro-
cesses.
Mutations of R280 differ from the mutations observed
with Asp278 with regards to their immunoreactivities with
a monoclonal antibody shown previously to prevent GM-
CSF binding. Thus, all R280 mutations and wild-type
GMR-a reacted with the antibody, whereas all D278 mu-
tants displayed enhanced immunoreactivity, suggesting a
structural difference and the possibility of intrachain salt
bridging with a positively charged residue, Lys191, on the
linker region of GMR-a. It is thus possible that the b turn
which presents R280 to the ligand is held in place by two
structural elements, a salt bridge conferred by Asp278 and
the p-charge interactions assigned to the WSXWS box
with a conserved Arg in the F9 strand, as discussed under-
neath (Fig. 1 and reference 36).
GMR-a and bc Preassociate in the Absence of Ligand.
The fact that GMR-aR280 mutants do not bind GM-CSF
when transfected alone but do so in the presence of bc, is
consistent with the view that GMR-a and bc associate in
Table 3. Kinetic Association Constants of Wild-type and Mutant GMR-a
GMR a 1 b
Antibody
reactivity Kinetic constants
Dissociation
constants
OD490 Kon Koff Koff/Kon Kd
Abs. min21M21 min21 nM nM
wild type 0.241 1.3 3 108 5.6 3 1023 0.04 0.03
R280M 0.210 1.4 3 107 1.3 3 1022 0.93 3.0
D278A/V279A 0.653 5.2 3 106 5.1 3 1023 0.98 1.33
D278Q/V279Q ND 7.5 3 106 8.2 3 1023 1.09 1.98
D278A 0.481 3.8 3 106 3.2 3 1023 0.84 2.5
D278N ND 1.4 3 107 2.0 3 1022 1.43 0.59
I281A/L282A ND 1.1 3 108 6.0 3 1023 0.06 0.05
I281Q/L282Q 0.297 3.4 3 107 8.2 3 1023 0.24 0.09
R258Q 0.285 0.9 3 108 6.2 3 1023 0.07 0.12
The kinetic association (Kon) and kinetic dissociation (Koff) constants of wild-type and mutated GMR-a were determined by using transfected NIH
3T3 cells as described in Materials and Methods and as shown in Fig. 4. The dissociation constants determined at equilibrium were estimated by anal-
ysis of full saturation curves for each mutant, using the program ALLFIT (9, 26). The reactivity of the different GMR-a mutants with the mono-
clonal anti–GMR-a were determined by immunoperoxidase as described in Fig. 2.
Figure 5. Ligand-induced biological response of NIH 3T3 cells ex-
pressing both GMR-aR280 mutants and bc. (Top) NIH 3T3 cells were
co-transfected with GMR-aR280 mutants and bc. Transfected cells were
then incubated for 40 h in serum-free medium supplemented with the in-
dicated concentrations of GM-CSF. Cell proliferation was evaluated by
[3H]thymidine incorporation as described in Materials and Methods. Data
are the mean of triplicate cultures. For each point, the standard error was
no more 15% of mean values. (Bottom) NIH 3T3 cells were transfected
with GMR-a mutants, bc, and c-fos promoter reporter construct. Trans-
fected cells were then incubated for 24 h in serum-free medium supple-
mented with the indicated concentrations of GM-CSF. c-fos promoter
activity was evaluated by measuring luciferase activity in cell extracts as
described in Materials and Methods. Data are the mean of duplicate cul-
tures.1947 Rajotte et al.
Figure 6. The F9–G9 loop of the second fibronectin domain of the GM-CSF, IL-3, and -5 a chain receptors: sequence alignment and three-dimen-
sional models and homology modeling of the erythropoietin receptor complex with its ligand. The alignment is adapted from Bazan (14) and Goodall
et al. (19). Residues in bold are shown through site-directed mutagenesis to be important for proper ligand binding (humgmcsfr, GMR-a, shown herein;
humil6r, IL-6R-a (17); fn10, fibronectin type III tenth repeat (16); humepor, EpoR (41, 42). Conserved residues within the F9 and G9 strands are boxed,
as well as the conserved WSXWS sequence. Comparison of the F9–G9 loop (yellow) facing helix D (red) of the ligand in the GMR-a, IL-3R-a, and IL-5R-a
models, highlights a possible electrostatic interaction between a positively charged residue, Arg (green), and a negatively charged residue, Asp or Glu (blue).
In GMR-a, R280 is at the tip of the b turn pointing towards the ligand, whereas the aspartic acid (D278, green) is in the vicinity of a lysine (K191, ma-
genta) located in the linker region between the two fibronectin domains. Note that in the IL-3 model, an aromatic residue on the F9–G9 loop, Tyr261, is
close to another aromatic residue, Phe113 from helix D. In the lower right panel, the extracellular domains of the two Epo receptor chains are shown
complexed with the modelized Epo hormone. The Epo–EpoR2 complex is based on the structure of the GH–GHR2 complex, and was generated as de-
scribed in the Materials and Methods. The p-charge interaction in EpoR consisting of one arginine (white) and two tryptophan (green) from the WSXWS
motif is illustrated. The two disulfide bridges formed between the four conserved cysteine are shown in blue.1948 Granulocyte/Macrophage Colony-stimulating Factor Receptor Assembly
the absence of GM-CSF (9, 37). This preassociation is
nonetheless of low affinity, and the presence of ligand re-
sults in stabilization of the a–b complex by 1,000-fold (9).
Although bc does not bind GM-CSF by itself, previous
data indicate that it can do so when associated with GMR-a.
The contact point was identified by scanning mutagenesis
of GM-CSF (31) and sequence alignment of GHR with bc
(19). Consistent with this result, our data clearly indicate
that bc binds the ligand even when associated with an a
chain that, by itself, no longer recognizes the ligand. In ad-
dition, our observations also suggest that the association of
GMR-a with bc is unlikely to generate additional GM-
CSF binding sites on GMR-a beyond those affected by the
R280 mutations.
Role of the F9–G9 Loop of Cytokine Receptors in Ligand
Binding. Evidence is provided here that mutagenesis of
members of the superfamily of cytokine receptors can be
directed to specific residues that are predicted to be at the
ligand–receptor interface through homology modeling with
the x-ray crystal structure of the hGH bound to its recep-
tor. It was previously shown that the functional interface of
growth hormone with its receptor is much smaller than the
physical interface and that electrostatic interactions are cru-
cial for the first step in ligand–receptor recognition (35). Our
data underscores the importance of a single charged residue
at the F9–G9 loop of the fibronectin-like domain of the
GM-CSF receptor, R280. For the GM-CSF receptor com-
plex, data reported here for GMR-a and elsewhere for bc
and GM-CSF indicate that the functional interface may be
restricted to a limited number of residues, GMR-aR280,
bc His367 (29, 30) and Tyr421 (38), and GM-CSF Asp112
and Glu21 (31). Furthermore, the on/off kinetics suggest
that the GMR-aR280–GM-CSFD112 interaction may de-
termine the recognition step, whereas the association with
bc would stabilize the complex possibly through interac-
tion of H367 and Tyr421 with the ligand.
Primary sequence alignment of the three closest mem-
bers of the cytokine receptors superfamily, IL-3R-a, -5R-a,
and GMR-a highlights the presence of one Arg at the F9–G9
loop in an otherwise diverging context (Fig. 6). Interest-
ingly, the IL-3 and -5 receptor complex models reveal that
a negatively charged residue (Glu or Asp) on the ligand is
in close contact with the Arg of the F9–G9 loop, indicating
a potential electrostatic interaction. Thus, the contribution
of the Arg residue to ligand recognition may also be ex-
tended to these receptors. Sequence divergence in this loop
among the GM-CSF, IL-3, and -5 a chain receptors sug-
gest that this region is likely to be important for the ob-
served specificity of the corresponding receptor subunit.
Furthermore, the F–G loop has been shown to contain
binding determinants. Short peptides containing the se-
quence Arg-Gly-Asp (RGD) from the F–G loop of the
tenth fibronectin type III repeat specifically block interac-
tions with integrins by binding integrins (39). The F9–G9
loop of IL-6R-a contains residues that are critical for IL-6
binding: E278-F279 and G282-E283 (17). Similarly, recent
data suggest the involvement of Y421 at the F9–G9 loop of
bc in high-affinity GM-CSF binding (38). Moreover, the
F9–G9 loop of cytokine receptors has, at its COOH-termi-
nal end, a highly conserved WS box that plays a crucial role
in maintaining the structure required for the presentation
of side chains involved in ligand binding (36).
The modeling of the Epo receptor and hormone was
performed using the same technique to compare our mod-
eling approach with a cytokine receptor of known crystal
structure (Fig. 6). Our model for EpoR illustrates the p-cation
interaction between the two Trp of the WSXWS motif
and an Arg of the F’ strand that was also observed in the
crystal structure (40). Furthermore, the two disulfide bridges
identified between the four conserved Cys in the crystal
structure are present in our model. Finally, our EpoR model
shows two phenylalanines, Phe93 (E–F loop) and Phe205
(F9–G9 loop), that point towards the hormone consistent
with their locating within the hydrophobic core formed
between the peptide and the receptor in the crystal struc-
ture (40) as well as their importance in ligand binding (41, 42).
In summary, the presence of a highly conserved struc-
tural element in the F9–G9 loop, the WS motif, imposes a
b turn to a loop that is highly divergent in sequence, allow-
ing the conserved Arg to be oriented towards the ligand
and further strengthens the possibility that this loop may be
involved in ligand interaction. The presence of the inte-
grin-binding determinant RGD in the F–G loop of the fi-
bronectin, which does not have a WS box, further under-
scores the crucial role of electrostatic interactions in ligand
binding for cytokine receptors with fibronectin-like do-
mains.
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